800 - 460 - 5832


Big news for OPDIVO®!
Mar 3, 2017

Big news announcing BC will cover the cost of the immuno-oncology treatment OPDIVO® for the treatment of eligible patients who have metastatic melanoma, locally advanced or metastatic pre-treated non-small cell lung cancer (NSCLC) and advanced or metastatic pre-treated renal cell carcinoma (RCC). This news comes following the agreement signed last month with the pan-Canadian Pharmaceutical […]

Read more ›
Melanoma, Metastatic Lung, and Kidney Cancer Patients a Step Closer to Receiving Immunotherapy!
Feb 16, 2017

As of this week, melanoma, metastatic lung, and kidney cancer patients are a step closer to receiving immunotherapy treatments. The pan-Canadian Pharmaceutical Alliance (pCPA) has reached a pricing agreement with Bristol Myers-Squibb for nivolumab (OPDIVO®), bringing the drug closer to being publicly funded and listed on provincial formularies for some patients. More information can be […]

Read more ›
Nov 23, 2016

Patient access to innovative new cancer treatments seriously limited by provincial funding recommendations across Canada TORONTO – NOVEMBER 22, 2016 – Health Canada recently conditionally approved an advanced new treatment option for Canadians battling metastatic melanoma. The treatment consists of a combination of two immuno-oncology agents: Opdivo + Yervoy, the first combination in the immunotherapy […]

Read more ›
Save Your Skin Celebrates #GivingTuesday in Canada
Nov 16, 2016

On November 29th, Giving Tuesday is coming to Canada! A compliment to Black Friday and Cyber Monday, #GivingTuesdayCa is a day that stimulates the community instead of the economy by facilitating donation to thousands of charities across Canada. There are many charities worth donating to on Giving Tuesday, and we always encourage helping your community […]

Read more ›
Health Canada Approves First-ever Combination of Two Immuno-Oncology Agents for Metastatic Melanoma
Oct 31, 2016

Health Canada approves the OPDIVO® + YERVOY® regimen for previously untreated patients with unresectable or metastatic melanoma  VANCOUVER – October 31,2016 – Canadians battling metastatic melanoma have new hope with a new treatment option just approved by Health Canada. This new treatment includes the first-ever combination of two immuno-oncology agents. Health Canada has granted conditional approval for the OPDIVO® + […]

Read more ›
ESMO (European Society for Medical Oncology) Breaks Records for Attendance and the Quality of Science Presented
Oct 12, 2016

  ESMO (European Society for Medical Oncology) Breaks Records for Attendance and the Quality of Science Presented Save Your Skin Foundation attends ESMO 2016 in Copenhagen, Denmark, taking part in the annual congress impacting the practice of oncology across the globe VANCOUVER, BRITISH COLUMBIA (October 12, 2016) – ESMO 2016 has broken records, not only of […]

Read more ›
Sep 20, 2016

With Dr. Alan Spatz, MD Director, Pathology Department, Jewish General Hospital & Professor, Pathology and Oncology, McGill University Thursday, October 13, 2016 at 12pm EDT, 10am MDT, 9am PDT To diagnose diseases such as cancer, a sample of tissue called a biopsy is taken from a patient and examined by a pathologist to determine if […]

Read more ›
Webinar Notice: Sunscreen 101 on September 1
Aug 26, 2016

Choosing the Right Sunscreen With Renée-Claude Lachapelle, Medical Development Specialist, L’Oréal Canada Thursday, September 1, 2016 at 12pm EST, 10am MST, 9am PST Choosing the right sunscreen can be difficult. When picking the right product, you may be asking yourself questions such as, what does sun protection factor (SPF) mean? Or, what’s the difference between an […]

Read more ›
Melanoma Through My Lens Reflection Project
Aug 17, 2016

My journey started in 2003 when I was diagnosed with stage IV malignant melanoma. I never dreamed melanoma could be something I could die from. From the moment I heard the word “cancer” my family and I began our search for information or support to help alleviate our fears and anxiety. When we came up […]

Read more ›